The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for ...
While the Supreme Court's ruling was directed at the advertising restrictions in section 503A of the Federal Food, Drug, and Cosmetic Act, it had the effect of invalidating the entire section ...
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's respiratory syncytial virus (RSV) vaccine. Just days before its ...
Some results have been hidden because they may be inaccessible to you